Chronic infection with hepatitis B virus (HBV) is a major cause of liver disease, particularly in the AsiaPacific region, contributing to cirrhosis, hepatic decompensation and hepatocellular carcinoma (HCC) [1, 2] . Liver damage is a consequence of the immune system's attempted clearance of HBV [3, 4] . Conventional therapies for chronic HBV (CHB) include direct antiviral agents (for example, lamivudine [3TC]) and immune modulating agents (for example, interferon [IFN] ), which reduce HBV replication in order to control disease progression [1] . However, IFN-based treatments are poorly tolerated and antiviral agent efficacy is limited by acquired drug resistance [1] . These shortcomings highlight the need for improved therapeutic approaches.
The innate immune response is the first line of host defence targeting exogenous pathogen infection through the recognition of pathogen-associated molecular patterns. The Toll-like receptors (TLRs) are the primary pathogen pattern recognition receptors involved in the innate response. Thirteen members of the TLR family have now been identified. TLR1-9 are common to human and mouse. TLR10 appears to be functional only in humans and TLR11-13 occur only in the mouse [5] [6] [7] . TLRs signal via their Toll/interleukin (IL)-1 receptor-domains to promote pro-inflammatory cytokine responses via two signalling pathways -the canonical MyD88-dependent pathway, and the MyD88-independent pathway [5] .
Introduction
The MyD88-dependent pathway is used by all TLRs with the exception of TLR3. Downstream signalling activates the transcription factors nuclear factor (NF)-κB and activator protein-1, which in turn induces the expression of genes involved in the inflammatory response, including tumour necrosis factor (TNF)-α, IL-1, IL-6 and IL-8. TLR7/8 and TLR9 are also able to use MyD88 to induce the expression of type-1 IFN. By contrast, the MyD88-independent pathway is used selectively by TLR3 and TLR4, which use the TIR-domain-containing adaptor inducing IFN-β (TRIF) to activate downstream interferon regulatory factor-3, subsequently inducing the expression of IFN-β. TRIF is also able to induce a late phase pro-inflammatory cytokine response via an alternate pathway of NF-κB activation.
Not surprisingly, pathogens have evolved strategies to manipulate these receptors and signalling pathways to circumvent the host immune response. The recent identification of the expression of TLRs on human hepatocytes by Visvanathan et al. [8] indicated that the hepatocyte itself might play a role in innate immune defence against the HBV in vivo. The observation that hepatocyte TLR2 expression was down-regulated in the setting of hepatitis B e antigen (HBeAg)-positive CHB, but up-regulated in HBeAg-negative CHB [8] , raised the possibility that TLR2 signalling might be an antiviral strategy employed by the hepatocyte to control HBV replication. Consequently, it also added increased weight to a possible role for the precore (PC) protein of HBV (HBeAg) in modulating TLR2 expression and signalling in vivo.
There are a number of human hepatoma cell lines that support HBV replication in vitro [9] . These include the ATCC HepG2 cell line, which supports the recombinant HBV baculovirus (BCV) transduction model [10] and the Huh-7 cell line, which supports transient transfection of infectious clones of HBV complimentary DNA (cDNA) in vitro [9] . Presently, there is little information concerning the use of cell-culture-based models for the study of innate immune responses or TLR-mediated events in the setting of HBV replication.
We have recently performed a comprehensive characterization of TLR signalling pathways in the ATCC HepG2 and Huh-7 cell lines [11] . A limited repertoire of TLR expression was observed, consistent with two previous studies of TLR gene expression [12, 13] . HepG2 cells expressed IL-1 receptor (IL-1R), TLR1, TLR2, TLR3 and TLR6 messenger RNA (mRNA), but minimal TLR4, TLR7 and TLR9 mRNA and no TLR5, TLR8 or TLR10 mRNA [11] . TLR2 forms heterodimers with either TLR1 or TLR6 to recognize specific ligands [5] [6] [7] . A similar expression profile was noted in the Huh-7 cell line [11] . In both cell lines, only the IL-1R and TLR2 were functional, however, and specific stimulation of these receptors resulted in MyD88-dependent NF-κB activation and induction of the pro-inflammatory cytokines TNF-α and IL-8 [11] . A number of different steps in the pathway were investigated to confirm specificity and physiological significance, including phosphorylation of NF-κB, increase of TNF-α, IL-8 and IL-6 mRNA expression, and TNF-α protein translation. A hierarchy of ligand response was noted, with potency of IL-1β>Pam-2-Cys (P2C; specific for the TLR2/TLR6 heterodimer) >P3C (specific for the TLR2/TLR1 heterodimer), respectively. No type-1 IFN response could be stimulated, consistent with previous reports that TLR2 does not activate the MyD88-independent signalling pathway in these cells [14] . Real time quantitative PCR (RT-qPCR) for induction of TNF-α mRNA was found to be the most sensitive assay, and the TNF-α enzyme immunoassay (EIA) was the least sensitive. Specifically, TNF-α protein was only detectable by EIA, at levels near the lower limit of detection (LLD) of the assay (8 pg/ml) following stimulation with IL-1β, but not P2C or P3C. This was believed to reflect the sensitivity of the EIA relative to the RT-PCR or reporter assays. The potency of IL-1β was approximately 10-fold higher than that of P2C, as measured by RT-qPCR, and by extrapolation of TNF-α production following P2C stimulation was predicted to fall below the LLD of the EIA.
Therefore, although hepatocyte cell lines were demonstrated to initiate a pro-inflammatory signalling cascade in response to TLR2 ligand stimulation, the physiological significance of these pathways was uncertain, given the absence or only very low level of detectable cytokine production at the protein level. Thus, the aim of this study was to investigate the potential antiviral effects of TLR2-specific signalling, within two human hepatoma cell lines, on HBV replication, in the presence or absence of HBeAg production.
Methods

Cell culture, transductions, transfections and ligand stimulation
Two cell lines were examined, namely the HepG2 (ATCC HepG2) and Huh-7 (Huh-7-SL) cell lines. HepG2 cell lines were maintained in minimum essential medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% heat-inactivated fetal calf serum, penicillin/ streptomycin and L-glutamine in a humidified 37°C, 5% CO 2 incubator. Replication-competent genotype D 1.3 unit length recombinant HBV-BCV (rHBV-BCV; see HBV infectious clones), was generated and purified as previously described [10, 15] . HepG2 cells were seeded into 60 mm plates (Becton Dickinson, San Jose, CA, USA). After overnight (16 h) incubation, the cells were transduced with rHBV-BCV at a multiplicity of infection (MOI) of 50 plaque-forming units (PFU) per cell [15] . Immediately after transduction, fresh medium was added. Cells were stimulated with particular treatments (control/antiviral drug/cytokine/TLR ligand) for 6, 24, 48 or 72 h prior to harvest. Each treatment was diluted in fresh medium, and added at the time of media change, rather than being added to each plate individually, to minimize dose variation. Consecutive passages of the same HepG2 subclone were used for each experimental set, to minimize experimental variation. Cell culture media was changed on days 1, 3 and 4 post-transduction and cultures harvested on day 5 according to protocol.
The Huh-7-SL cell line (kindly provided by Stan Lemon, UTMB, Galveston, Texas) was maintained in Dulbecco's modified Eagle's medium (Gibco-BRL, Grand Island, NY, USA) supplemented with 10% heatinactivated fetal calf serum, penicillin/streptomycin in a humidified 37°C, 5% CO 2 incubator [14] . For transfection, cells were seeded into 60 mm dishes and allowed to adhere overnight. On the following day, when the cells were 60-80% confluent, the culture medium was replaced with fresh medium. Sets of replicate cultures were transiently transfected [16] with 5 µg of each HBV construct by using 8 µl of FuGENE 6 transfection reagent (Roche Diagnostics, Mannheim, Germany), according to the manufacturer's instructions. The culture medium was changed on day 2 or day 3, and the cells were harvested on day 5 post-transfection. Cell viability was monitored using the MTT assay as described previously [15, 17] .
Plasmids and cytokines
The small interfering RNA (siRNA) for TLR2 expressing plasmid (psiRNA) was purchased from InVivoGen (San Diego, CA, USA). IL-1β and TNF-α were purchased from Roche (Indianapolis, IN, USA). The TLR2 ligand P2C was purchased from InVivoGen. 3TC was purchased from Moravek (Brea, CA, USA). Human IFN-α was obtained from Sigma (Clayton, VIC, Australia).
HBV infectious clones
A replication competent plasmid containing a 1.3× genome-length HBV construct (genotype D, subtype ayw) was cloned into the multiple cloning region of BCV transfer vector pBlueBac4.5 (Invitrogen) to create a new plasmid, designated the wild-type parent (pWT) [10, 17] . Two additional HBV transfer plasmids, each containing different mutations, were generated from pWT by site-directed mutagenesis using a QuikChange Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA, USA) as described by Chen et al. [15] and included the PC stop codon (G1896A) and the double basic core promoter (BCP) mutant, A1762T, G1764A [15] . Both HBV mutants are replication competent in vitro [15] . Transduction of HepG2 cells with the double BCP mutant resulted in a reduced titre of HBeAg in the cell cultures supernatant (50 Paul Ehrlich International Units (PEIU)/ml versus 150 PEIU/ml for wild-type [WT] HBV) whilst the PC (G1896A PC stop codon mutant) HBV mutant produces no HBeAg at all.
Analysis of replicative intermediates
HBV core particles were isolated from HepG2 and Huh-7 cells as described previously [9, 10] . Briefly, after removing the supernatant, cells were washed with phosphate-buffered saline (PBS) and then lysed with 800 µl of 0.5% Nonidet P-40 in PBS for 20 min at 4°C. Cell lysates were then transferred to microfuge tubes and spun at 13,000 rpm for 5 min to remove the nuclei. Unprotected DNA was removed by incubating the samples with 20 U of RNase-free DNase I (Roche Diagnostics, Branchburg, NJ, USA) for 1 h at 37°C. The incubation mixture was then adjusted to 10 mM EDTA, 1% SDS and 100 mM NaCl. Proteinase K was then added to the samples at a final concentration of 0.5 mg/ ml and incubated for a further 4 h at 37°C. Replicative intermediates were then isolated following sequential phenol/chloroform extractions and isopropanol precipitation as described previously [9, 10] . Precipitated nucleic acids were resuspended in 5 mM EDTA and digested with 20 U of DNase-free RNase I (Roche Diagnostics, Branchburg, NJ, USA) for 1 h at 37°C [18] . Replicative intermediates were then analysed by electrophoresis, Southern blotting and autoradiography as described previously [9, 15, 19] .
Analysis of secreted hepatitis B e antigen
Medium from HepG2 cells was collected, centrifuged at 3,000 rpm to remove cellular debris and transferred to clean tubes. The amount of HBeAg secreted into the cell culture medium was then qualitatively determined using a commercially available EIA (Abbott Laboratories, Chicago, IL, USA) and quantitatively using the Abbott Architect platform with cross-reference to the Paul Ehrlich HBeAg reference standard (Paul Ehrlich Institute, Langen, Germany) so that the amount of HBeAg was expressed in PEIU/ml similarly as described by Fried et al. [20] .
Analysis of hepatitis B core antigen and nucleocapsid production
Hepatitis B core antigen (HBcAg) was detected in cells by immunoblot using anti-core antibodies purchased from Abcam (Cambridge, MA, USA; mouse monoclonal) and Dako (Glostrup, Denmark; rabbitpolyclonal), followed by an anti-rabbit or anti-mouse horseradish peroxidase secondary antibody. Protein bands were visualised using chemiluminescence. Two measures of HBcAg protein were determined: total intracellular HBcAg protein production and HBV nucleocapsid formation.
Hepatitis B core protein detection
Cells were harvested after 5-7 days following transduction/transfection by dissolving in a 2% SDS lysis buffer (fully denaturing) containing complete protein inhibitors and mixed with 5× Laemmli loading dye as previously described [9, 10, 15] . Proteins were then electrophoresed through a 12% polyacrylamide gel, transferred to Hybond-C membrane and detected using either monoclonal or polyclonal antibodies against HBcAg (anti-HBc) as described above in order to measure the total amount of cellular HBcAg protein synthesised.
HBV nucleocapsid detection
Nucleocapsid particles were isolated from transfected cells following cell lysis in a buffer containing 0.5% Nonidet P-40, 10 mM Tris pH 7.5, 50 mM NaCl and 1 mM EDTA and the nuclei were removed by centrifugation at 13,000 g. These nuclei-free cell lysates were subjected to digestion with 20 U DNase I and were stored at 4°C. A quantity of 50 µg of each lysate was then subjected to electrophoresis through a 1.2% (w/v) non-denaturing agarose gel in Tris-acetate EDTA buffer as described by Melegari et al. [21] . Nucleocapsids were detected by western blot analysis using Dako polyclonal anti-HBc as per standard procedures (see Analysis of hepatitis B core antigen and nucleocapsid production) [9, 10, 15] .
siRNA for TLR2
Huh-7 cells were co-transfected with a total of 4 µg of plasmid DNA comprising either pWT (HBV):plasmid empty vector (pEV) in a 2:2 ratio or pWT:pEV:psiRNA in a 2:1:1 ratio using FuGENE 6 Transfection Reagent (Roche Diagnostics, Mannheim, Germany). siRNA vectors obtained from InVivoGen have been validated by the company and guarantee a minimum knockdown of target mRNA>70%; this has been independently confirmed for TLR2 knockdown [22] . Cells were treated for 3 days, with fresh media containing either P2C (1,000 ng/ml), IFN-α (10 3 IU/ml), IL-1β (10 ng/ nl), TNF-α (10 ng/ml) or 3TC (0.01 µM). Nucleocapsid particles were isolated as described (see HBV nucleocapsid detection). Following DNase I digestion, the sample was divided in two, with half being used for nucleocapsid detection and the remaining half being processed for the isolation of replicative intermediates and subsequent detection by Southern blot hybridization as described (see Analysis of replicative intermediates). Aliquots of these samples were also harvested for total HBcAg by dissolving the cells in Laemmli buffer and processing for polyacrylamide gel electrophoresis as described above (see Analysis of replicative intermediates).
Quantitative PCR
The expression of TNF-α mRNAs following ligand stimulation was tested as previously described [11] . In brief, for each of the cell lines, live cells (2×10 5 per well) were seeded into 6-well plates; 24 h later, cells were stimulated before harvesting at the indicated times. Total cellular RNA was extracted using the RN easy MiniKit (Qiagen, Germantown, MD, USA) according to the manufacturer's instructions and eluted into 50 µl of nuclease-free water. cDNA was synthesized using the ABI High capacity RT kit (Applied Biosystems, Foster City, CA, USA) as per the manufacturer's instructions. TaqMan real-time PCR was performed with 50 µg of cDNA using the AssaysOn-Demand Gene Expression Products (Applied Biosystems) and an ABI Prism 7000 Sequence Detection System (Applied Biosystems). The relative quantities of mRNA were determined using the comparative cycle threshold (C t ) method, where the amount of target DNA was normalized to the internal control, RPLP0 ribosomal cDNA and expressed relative to the baseline unstimulated control cDNA (2 -∆∆Ct ). RPLP0 was chosen as the internal control after comparison with 18 S and GAPDH. Probe sets resulting in C t >35 were not analysed and scored as undetectable.
Enzyme immunoassay
TNF-α was measured in cell culture supernatant by capture EIA using the OptEIA Set (BD Biosciences, Franklin Lakes, NJ, USA) according to the manufacturer's specifications. The LLD of the assay was 0.008 ng/ml.
Statistical analyses
Two-tailed Student's t-tests were used to compare results between quantifiable experiments where possible. An α-value of 0.05 was used to determine deviations between treatments that could not be explained by normal sampling variation alone. Standard deviations are shown as error bars for most experiments presented.
Results
IL-1/TLR2 signalling inhibits HBV replication in hepatoma cells in vitro
Stimulation with IL-1β inhibited replication of HBV The effect of MyD88 signalling on HBV replication was firstly investigated using IL-1β, which has a common downstream signalling pathway with TLRs via its Toll/ IL-1 receptor domain. IL-1β was chosen as proof-ofprinciple and positive control, as hepatocytes have previously been shown to posses intact IL-1R and previous reports suggested that, in an alternative cell culture model, HBV replication was inhibited in vitro [23] . A timecourse experiment was performed using the dose of IL-1β identified to induce maximal TNF mRNA expression (data not shown). HepG2 cells were transduced with WT rHBV-BCV constructs at an MOI of 50 PFU per cell. All cells were harvested at 4 days post-transduction; cells were stimulated with IL-1β (10 ng/ml) for 6, 24, 48 or 72 h prior to harvest. 3TC was used as the positive control at the 50% inhibitory concentration in this system of 0.01 µM [15, 24] . IL-1β was found to exert a modest antiviral effect, in which maximal reduction of intracellular single-stranded HBV replicative intermediates was observed after 24-48 h of stimulation (Figure 1 ). The inhibition of replication was attenuated beyond 48 h, perhaps consistent with the development of tolerance. As expected, the 3TC effect was seen to cumulatively increase throughout the timecourse [25] . Thus, 48 h was chosen as the duration of stimulation with ligands for all subsequent experiments.
Stimulation with the TLR2 ligand P2C inhibited replication of HBV
The rHBV-BCV-HepG2 system was then used to test for an antiviral effect of the TLR2 ligand P2C. HepG2 cells were again transduced with WT rHBV-BCV constructs at an MOI of 50 PFU per cell. After 2 days of culture, cells were stimulated for 48 h with a range of concentrations of P2C (10, 100 and 1,000 ng/ml; Figure 2A ). The cells were also separately treated with TNF-α (10 ng/ml) and 3TC (0.01 µM) as positive controls, with TNF-α inhibiting replication via an alternate pathway of NF-κB induction [24] , and 3TC via HBV polymerase inhibition [15, 16] . The results, summarized in Figure 2B , show a dose-response inhibition of HBV viral replication using P2C. P2C exerted a moderate inhibition of WT HBV replication, but the maximum concentration of 1,000 ng/ml was less potent than either TNF-α or 3TC as an inhibitor of WT HBV replication. 
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Testing of HBV mutants defective for HBeAg production
The experiment was then repeated using viruses defective for HBeAg production: the G1896A PC variant, which does not produce HBeAg, and the A1762T/G1764A BCP variant, which produces approximately 30% of the HBeAg that the WT virus produces. The inhibitory effect of P2C on both viruses was of similar magnitude (Figure 3A to 3D) , with the effect on the BCP variant being greater than the PC variant (80% reduction versus 35% reduction at P2C at a dose of 1,000 ng/ml). The P2C antiviral effect on the PC variant (35% inhibition at P2C of 1,000 ng/ml; Figure 3A and 3B) was of a similar order of magnitude to its effect on the WT virus (45% inhibition, at P2C of 1,000 ng/ml; Figure 2A and 2B).
HBeAg secretion was not inhibited by the TLR2 ligand P2C
The cell culture supernatants from the rHBV-BCV experiments were then assayed for HBeAg titre. Despite the Southern blots showing significant decreases in HBV replicative intermediates, no effect on HBeAg production was evident, for either WT HBV or BCP Mutant HBV ( Figure 2C and 3E ). This was consistent with an antiviral block to the replication cycle at a posttranscriptional level.
The TLR2 ligand P2C inhibited HBV capsid formation but not the total amount of HBcAg produced in cells Cytokines, including TNF-α, IFN-α/β and IFN-γ have previously been shown to inhibit HBV replication by inhibiting nucleocapsid formation [26] [27] [28] . In order to gauge the effect of P2C on HBV nucleocapsid formation, treated cells were harvested and processed in either Laemmli buffer (total HBV core protein production) or nonidet P-40 (NP-40; nucleocapsid formation) and analysed by denaturing or non-denaturing gel electrophoresis. Unfortunately, very little core protein was reliably detected following transduction of HBV, likely 
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reflecting the lower replication yield of the rHBV-BCV system relative to transfection systems [9, 15, 16] . These experiments were then repeated using transient transfection of WT HBV-expressing plasmids, in the Huh-7 cell line. This transient transfection system achieves higher levels of HBV replication than the rHBV-BCV model [9, 15, 16] , and core protein could be detected by immunoblot. TNF-α, IFN-α and 3TC were included as controls. Treatment of the transfected Huh-7 cells with P2C or any of the other cytokines had no effect on the total level of HBV core protein produced in the Huh-7 cells (data not shown). However, when the cells were treated with P2C and the lysates analysed for nucleocapsid formation, a decrease (≥30% reduction) in the A B levels of viral capsids was observed (Figure 4 ). These findings were reproducible. A post-transcriptional antiviral effect of TNF-α and IFN-α on nucleocapsid formation was also observed, whereas 3TC was shown to have no effect, as previously described [15, 24] ( Figure 4) .
The antiviral effect of P2C was blocked in the presence of siRNA for TLR2
In order to demonstrate the specificity of the antiviral effect on HBV nucleocapsid assembly following TLR2 stimulation, Huh-7 cells were again cotransfected with HBV DNA plus an expression vector of siRNA for TLR2 (psiRNA). The same experimental protocol described in Methods used and the NP-40 lysates from the cells were prepared, harvested and processed for HBV core (fully denaturing immunoblot; Figure 5A ) levels as well as nucleocapsid (non-denaturing immunoblot; Figure 5B ) formation. Figure 5A shows that there was no difference (that is, <30% reduction) in the presence or absence of siRNA for TLR2 for the amount of core protein produced following any of the treatments ( Figure 5A ). However, in the presence of the siRNA TLR2, under non-denaturing conditions ( Figure 5B ), the antiviral effect of TLR2 stimulation on nucleocapsid production was abolished.
The antiviral effect of P2C was not caused by the secondary induction of TNF-α in HepG2 or Huh-7 cells
To exclude the possibility that secondary TNF-α induction might be responsible for the inhibition of viral replication observed following TLR2 stimulation, the HepG2 and Huh-7 cell lines were exposed to increasing doses of TNF-α. The output measured was the induction of TNF-α mRNA itself, as measured by RT-PCR, as TNF-α had been previously shown to induce expression of TNF-α mRNA via the TNF receptor (positive feedback) [11] , and in this cell culture system induction of TNF-α was the most sensitive marker for activation of NF-κB signalling. The dose range was chosen on the basis of the concentration of TNF-α protein detected by EIA in the cell culture supernatant in the initial experiments, when maximal doses of IL-1β resulted in a peak concentration of 0.008 ng/ml TNF-α in the cell culture supernatant. Induction of TNF-α mRNA was detectable only at doses of ≥0.10 ng/ml TNF-α in both cell lines ( Figure 6A for HepG2 and Figure 6B for Huh-7 cells), indicating that secondary induction of TNF-α was probably not responsible for the antiviral effect observed in either cell culture system.
The antiviral effect of P2C was not caused by cytotoxicity
Because cytokine treatment can cause toxicity directly and thereby affect viral replication, three parallel sets of HepG2 cells were continuously exposed to P2C (10, 100 and 1,000 ng/ml), IL-1β (0.01, 0.1, 1 and 10 ng/ml) and TNF-α (10 ng/ml) for 7 days. The cell monolayers remained intact for the entire duration of the assay, and daily microscopic examination revealed no evidence of cytotoxicity. The MTT uptake by viable cells was measured by spectrophotometry as described in the Methods. The agents were not cytotoxic at the concentrations used, confirming that the observed inhibitory effect of on HBV replication was not an artefact caused by cytotoxicity (data not shown). Similar results were found with the Huh-7 cells (data not shown). 
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Discussion
The HepG2 cells and the Huh-7-SL cell lines used in this study have been previously shown by our group to respond to the TLR2 ligand P2C in functional assays [11] . The finding of functional TLR2 expression on HepG2 and Huh-7-SL cells provided the opportunity to examine human cell culture models that would allow testing of the direct effect of TLR2 signalling on the replication of HBV in vitro. In the rHBV-BCV model, 48 h of stimulation with P2C significantly inhibited WT HBV DNA replication. A dose-dependent effect was observed, with core-associated HBV DNA replication inhibited up to 90% at maximal dose. In the transient transfection system, nucleocapsid formation was also significantly reduced. The HBeAg defective strains of HBV were also similarly inhibited by P2C.
Antiviral cytokines have been shown to inhibit viral replication post-transcriptionally. In the case of TNF-α, this can occur via destabilization of HBV capsid formation, a crucial step in the viral replication pathway [26] . Type-1 IFNs have also been shown to interfere with capsid formation [28] . The observation in the rHBV-BVC HepG2 system, that HBV DNA replication was inhibited, yet HBeAg secretion was preserved, suggested that the TLR2 anti-HBV effect was acting at the post-transcriptional level. Post-transcriptional viral replication events were therefore investigated. This was not possible in the HepG2 cells, as the level of core protein generated by the rHBV-BCV model was below the threshold of sensitivity for western blot. Using the transient transfection model in Huh-7 cells, TLR2 stimulation was shown to reduce HBV nucleocapsid formation, but not the total amount of HBcAg produced by these cells. The inhibitory effect attributable to P2C was comparable to the known anti-HBV cytokine TNF-α [24] , but less effective than the potent nucleoside analogue 3TC. That the antiviral hierarchy observed in the rHBV-HCV HepG2 system (TNF-α>P2C) was not observed in the nucleocapsid assay was interesting. Although this might have related to differences in TNF-α-stimulated signalling pathways between the two cell lines, it was felt more likely that this reflected differences between the models. In the Huh-7 transfection model, HBV replication was driven by the powerful cytomegalovirus promoter rather than endogenous promoters; in addition, the nucleocapsid assay was less sensitive than the Southern blot for coreassociated HBV DNA. As a result, a more subtle distinction between the P2C and TNF-α antiviral effect was likely not possible. Collectively, the data suggests that activation of the TLR2 signalling pathway leads to reduced nucleocapsid formation and pregenomic RNA packaging, thus blocking subsequent reverse transcription and DNA replication [29] .
The mechanism whereby activation of TLR2 inhibits HBV replication remains unresolved. Whether this is via direct targeting of DNA replication by a TLR2 signalling intermediate or the induction of a TLR2 dependent gene is yet to be determined. A direct role for secondary cytokine induction is possible, but unlikely from the data presented. TNF-α is a canonical pro-inflammatory cytokine pathway induced by the MyD88-dependent signalling pathway, and is known to inhibit HBV in vitro [24] . However, the finding that no TNF-α was detectable in either the cell culture supernatant or cellular lysates following stimulation with P2C suggests that a novel antiviral cytokine might be involved. Furthermore, when the HepG2 cells were stimulated with TNF-α, no pro-inflammatory response was seen until the doses used were at least 10-fold higher than that observed in cell culture supernatant following highdose IL-1β stimulation. It is therefore reasonable to conclude that the antiviral effect of P2C, a weaker proinflammatory stimulus than IL-1β, was unlikely to have been mediated by secondary TNF-α induction. We have previously shown that IL-8 expression is also induced by TLR2 stimulation in these cell lines [11] . Although IL-8, a chemokine, is likely to play a role in the immunopathogenesis of HBV infection in vivo, there is no literature to support a direct anti-HBV effect of IL-8 on hepatocytes. Furthermore, we have previously shown in these cell lines that the fold-increase in IL-8 gene expression observed in response to P2C stimulation was less than that for TNF-α [11] , which itself was below the threshold for antiviral effect. Therefore, we believe that IL-8 is an unlikely candidate as a direct antiviral cytokine. As no type-1 IFN response occurs following TLR2 stimulation in these cell lines, the possibility of a novel antiviral mechanism is worthy of further investigation. It was notable that IL-1β, in contrast to P2C, did not significantly reduce nucleocapsid accumulation, consistent with distinct antiviral mechanisms, and suggesting distinct intracellular signalling downstream of TLR2 and IL-1R, despite sharing the canonical MyD88-dependent pathway of NF-κB induction. The molecular mechanism responsible for the antiviral effect of TLR2 therefore requires further investigation. This is the first study that demonstrates a direct role for hepatocyte TLR signalling as an anti-HBV mechanism in human hepatoma cell lines. Previous work using the HBeAg-positive HBV-transgenic mouse model has identified only an indirect role for liver non-parenchymal cell TLR signalling as an antiviral mediator via induction of type-1 IFNs [30] . TLR ligand stimulation of the HBV-Met cell line, an immortalized mouse hepatocyte cell line that contains the HBV transgene, did not have any antiviral efficacy [30, 31] . The conclusion was drawn that, at least in these mouse models, hepatocyte TLRs were not functional. There might therefore be interspecies variation in the expression and functional significance of TLRs. It should also be noted that the HBV transgenic mouse is a fundamentally different model of HBV replication, in which HBV is transcribed off the HBV transgene, cccDNA is not produced, and the intracellular milieu of transcription and translation factors substantially differs from the hepatoma cell culture models used in this study.
We have previously observed that patients with HBeAg-negative CHB display increased TLR2 expression and function on peripheral blood mononuclear cells, Kupffer cells and hepatocytes, and decreased levels of viral replication, relative to patients with HBeAgpositive CHB [8] We interpret this as suggesting that the production of the HBeAg represents an important immune evasion mechanism in vivo. In the in vitro models studied here, then, we were surprised to observe that the antiviral effect of P2C on HBV replication, was similar for all three viral constructs, including the PC and BCP variant viruses which are associated with either an absolute or relative decrease in HBeAg production, respectively. Greater potency of antiviral effect was not observed of the TLR2 ligand effect in vitro. Several possibilities might explain this discrepancy. First, it might be that HBeAg does play a direct immunoevasive role in vivo, but that the target is not the hepatocyte. The peripheral monocyte is a potential candidate, consistent with the inhibitory effect of PC conditioned media on monocyte TLR2 signalling previously described [8] . Second, it is possible that the HBeAg PC effect occurs only in the absence of other potentially immunostimulatory HBV proteins, such as HBsAg, as occurs in the extracellular environment.
In conclusion, we have shown that hepatocytes can play an important innate immune surveillance role directly within the liver itself and can no longer be considered as merely passive bystander cells. The finding of an antiviral effect in vitro provides support for the clinical observation that TLR2 plays an important role in the pathogenesis of CHB. It is also proof of principle that TLR ligands might have therapeutic potential. It will now be possible to interrogate different cell culture models in more detail for the molecular basis of the observed antiviral effect. These cell culture models should now prove a valuable tool for the further development of TLR ligands as novel antiviral agents.
